$ATAI

AtaiBeckley Inc (ATAI) shares surged 59% after-hours on reports that Eli Lilly (LLY) is nearing a deal, according to Bloomberg. The terms were not disclosed, but Lilly is negotiating at a premium. AtaiBeckley develops psychedelic-based mental health treatments, with its lead asset BPL-003 in late-stage development. Lilly's neuroscience segment generated $1.39 billion in 2025 revenue, with growth driven by Kisunla, an Alzheimer’s treatment.

The US premerger antitrust review period for Eli Lilly's acquisition of AtaiBeckley expired on August 28, per a regulatory filing. This clears a key hurdle for the merger between the pharmaceutical giant and the psychiatric biotech firm.

AtaiBeckley's merger with Eli Lilly cleared the U.S. HSR waiting period and progressed in UK and Australia reviews. The merger will make AtaiBeckley a subsidiary of Eli Lilly, with the Australian review set to conclude by September 10, 2026. According to the companies, the UK review has not raised further questions as of August 21, 2026.

The Hart-Scott-Rodino waiting period for Eli Lilly's merger expired on August 28, according to Reuters. This period is a review process under U.S. antitrust law.

AAPL, ATAI, and UNH stocks reached 52-week highs. AAPL rose 2% after China approved its AI service and HSBC upgraded it to 'Buy' with a $366 target. ATAI surged 33% following its acquisition by Eli Lilly for up to $9.25 per share. UNH gained 1% after Q2 earnings beat estimates and raised its full-year profit outlook.

Eli Lilly acquired AtaiBeckley for $2.8B to advance psychedelic drugs for mental health. The Trump administration supports research, aiming to fast-track approvals. Psychedelics, like psilocybin and MDMA, are being studied for treatment-resistant disorders. Publicly traded companies, including Definium Therapeutics and Compass Pathways, are developing these drugs, with potential FDA decisions this year.

Pharmaceutical companies have invested over $5 billion in psychedelic-derived medicines, with Eli Lilly, AbbVie, and Otsuka acquiring firms like AtaiBeckley, Gilgamesh, and Transcend. Compass Pathways' COMP360 is in FDA review for a 2027 launch. The market is projected to reach $11.8B-$14.9B by 2034-2035, driven by high demand for depression treatments. Companies are developing short-acting analogs to reduce clinic stay times.

Biotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.

AtaiBeckley Inc. (ATAI) shares hit a 52-week high of $7.26, up 86.98% over one year and 77% year-to-date, according to Investing.com. The stock also moved after Eli Lilly agreed to acquire AtaiBeckley for $6.75 per share upfront, valuing it about $2.8B plus a contingent value right up to $2.50. Analysts issued mixed rating and price-target changes.

The article discusses how legalization of psychedelic medicine is increasing commercialization and regulatory costs for Schedule I research. It cites Eli Lilly’s $2.8 billion acquisition of Atai Life Sciences/AtaiBeckley and describes Oregon’s Measure 109, where psilocybin sessions cost $850 to $3,000 and OHA proposed higher fees. It also notes New Jersey’s pilot favoring synthetic psilocybin.